These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10679807)

  • 1. The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin.
    Sandler SG; Novak SC; Roland B
    Am J Hematol; 2000 Mar; 63(3):156-8. PubMed ID: 10679807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune thrombocytopenic purpura - current management practices.
    Sandler SG; Tutuncuoglu SO
    Expert Opin Pharmacother; 2004 Dec; 5(12):2515-27. PubMed ID: 15571469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of immune thrombocytopenic purpura in children : current concepts.
    Shad AT; Gonzalez CE; Sandler SG
    Paediatr Drugs; 2005; 7(5):325-36. PubMed ID: 16220997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of multiple passively acquired alloantibodies following infusions of IV Rh immune globulin.
    Rushin J; Rumsey DH; Ewing CA; Sandler SG
    Transfusion; 2000 May; 40(5):551-4. PubMed ID: 10827257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serologic aspects of treating immune thrombocytopenic purpura using intravenous Rh immune globulin.
    Savasman CM; Sandler SG
    Immunohematology; 2001; 17(4):106-10. PubMed ID: 15373575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ABO and Rh blood type on the response to intravenous immune globulin (IVIG) in children with immune thrombocytopenic purpura (ITP).
    Sturgill MG; Nagabandi SR; Drachtman RA; Ettinger AG; Rubin J; Ettinger LJ
    J Pediatr Hematol Oncol; 1997; 19(6):523-5. PubMed ID: 9407938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group.
    Warrier I; Bussel JB; Valdez L; Barbosa J; Beardsley DS
    J Pediatr Hematol Oncol; 1997; 19(3):197-201. PubMed ID: 9201140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy.
    Simpson KN; Coughlin CM; Eron J; Bussel JB
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):58-64. PubMed ID: 9523750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura.
    Kane I; Ragucci D; Shatat IF; Bussel J; Kalpatthi R
    Br J Haematol; 2010 Apr; 149(1):79-83. PubMed ID: 20096011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous Rh immune globulin for treating immune thrombocytopenic purpura.
    Sandler SG
    Curr Opin Hematol; 2001 Nov; 8(6):417-20. PubMed ID: 11604585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
    Tarantino MD; Young G; Bertolone SJ; Kalinyak KA; Shafer FE; Kulkarni R; Weber LC; Davis ML; Lynn H; Nugent DJ;
    J Pediatr; 2006 Apr; 148(4):489-94. PubMed ID: 16647411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid irreversible encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura.
    Christopher K; Horkan C; Barb IT; Arbelaez C; Hodgdon TA; Yodice PC
    Am J Hematol; 2004 Nov; 77(3):299-302. PubMed ID: 15495245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura.
    Kumar M; Vik TA; Johnson CS; Southwood ME; Croop JM
    Am J Hematol; 2005 Mar; 78(3):181-7. PubMed ID: 15726607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.
    Tarantino MD; Madden RM; Fennewald DL; Patel CC; Bertolone SJ
    J Pediatr; 1999 Jan; 134(1):21-6. PubMed ID: 9880444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single dose of anti-D immunoglobulin raises platelet count as efficiently as intravenous immunoglobulin in newly diagnosed immune thrombocytopenic purpura in Korean children.
    Son DW; Jeon IS; Yang SW; Cho SH
    J Pediatr Hematol Oncol; 2008 Aug; 30(8):598-601. PubMed ID: 18799936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.
    Donga PZ; Bilir SP; Little G; Babinchak T; Munakata J
    J Med Econ; 2017 Nov; 20(11):1200-1206. PubMed ID: 28882075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rho (D) immune globulin i.v. for prevention of Rh isoimmunization and for treatment of ITP.
    Med Lett Drugs Ther; 1996 Jan; 38(966):6-8. PubMed ID: 8544794
    [No Abstract]   [Full Text] [Related]  

  • 19. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.
    Darabi K; Abdel-Wahab O; Dzik WH
    Transfusion; 2006 May; 46(5):741-53. PubMed ID: 16686841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada.
    Pettigrew M; Garces K; Deuson R; Kassis J; Laroche V
    J Med Econ; 2013; 16(2):318-26. PubMed ID: 23216012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.